Semaglutide is a GLP-1 receptor agonist primarily used for weight management and blood sugar control. This peptide is administered once weekly via subcutaneous injection, with a gradual increase in dosage over several weeks to improve tolerability and maximize therapeutic effect.
- Gradual dose escalation protocol to minimize side effects.
- Administered once weekly for convenience.
- Helps reduce appetite and improve glycemic control.
- Requires insulin syringes for precise unit measurements.
Reconstitution
Vial strength
10 mg
Bacteriostatic water
3 mL
Concentration
3.33 mg/mL
1 unit = 0.01 mL = 33.3 mcg
- 1Draw 3.0 mL of bacteriostatic water using a sterile syringe.
- 2Slowly inject the water down the inside wall of the Semaglutide vial to avoid excessive foaming.
- 3Gently swirl or roll the vial until the powder completely dissolves; do not shake.
- 4Label the reconstituted vial with the date and store it in the refrigerator at 2–8 °C (35.6–46.4 °F), protected from light.
- 5Use the reconstituted solution within 28 days for optimal potency and safety.
Dosing schedule
| Phase | Dose | On a U-100 syringe |
|---|---|---|
| Weeks 1–4 | 250 mcg (0.25 mg) | 7.5 units (0.075 mL) |
| Weeks 5–8 | 500 mcg (0.5 mg) | 15 units (0.15 mL) |
| Weeks 9–12 | 1000 mcg (1.0 mg) | 30 units (0.30 mL) |
| Weeks 13–16 | 1700 mcg (1.7 mg) | 51 units (0.51 mL) |
| Weeks 17+ (Maintenance) | 2400 mcg (2.4 mg) | 72 units (0.72 mL) |
Protocol detail
| Weeks 1–4 | 250 mcg (0.25 mg) once weekly to establish baseline tolerance. |
|---|---|
| Weeks 5–8 | 500 mcg (0.5 mg) once weekly. |
| Weeks 9–12 | 1000 mcg (1.0 mg) once weekly. |
| Weeks 13–16 | 1700 mcg (1.7 mg) once weekly. |
| Weeks 17+ (Maintenance) | 2400 mcg (2.4 mg) once weekly as the target maintenance dose. |
Overview at a glance
| Goal | Support chronic weight management through GLP-1 receptor activation, leading to reduced appetite and improved metabolic parameters. |
|---|---|
| Schedule | Weekly subcutaneous injections for 16–20+ weeks with gradual dose escalation. |
| Dose Range | 250 mcg (0.25 mg) to 2400 mcg (2.4 mg) weekly with stepwise titration every 4 weeks to improve tolerability. |
| Reconstitution | 3.0 mL of bacteriostatic water per 10 mg vial (~3.33 mg/mL) for accurate unit measurements on standard insulin syringes. |
| Storage | Lyophilized powder frozen at −20 °C (−4 °F); reconstituted solution refrigerated at 2–8 °C (35.6–46.4 °F) and used within 28 days; avoid repeated freeze–thaw cycles. |
How it works
Semaglutide actively engages the GLP-1 receptor, sharing significant structural similarity with natural human GLP-1. This action leads to multiple beneficial effects, including decreased appetite and food intake via central nervous system mechanisms, a slower rate of gastric emptying, and enhanced blood sugar control through insulin release that depends on glucose levels. Its extended lifespan of approximately seven days results from its ability to bind to albumin and resist degradation, allowing for convenient once-weekly dosing. Clinical studies confirm that when combined with lifestyle adjustments, Semaglutide can lead to substantial weight reduction.
Reported effects
- Significant weight loss (10-15% body weight reduction)
- Improved glycemic control
- Reduced appetite and food intake
- Potential cardiovascular benefits
- Convenient once-weekly dosing
Reported side effects
- Nausea, vomiting, diarrhea, constipation, abdominal pain (most common)
- Injection-site reactions (redness, swelling)
- Hypoglycemia risk (when combined with other medications)
- Rare reports of pancreatitis, gallbladder disease
Storage
Lyophilised (unmixed)
Freeze at -20 °C (-4 °F)
After reconstitution
Refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days
Supplies
| Peptide vials | Quantity depends on cycle length (e.g., 1 vial for 8-12 weeks, 3 vials for 20+ weeks) |
|---|---|
| Insulin Syringes (U-100) | One per week of protocol |
| Bacteriostatic Water | Approximately 3.0 mL per 10 mg vial (e.g., one 10 mL bottle for up to 3 vials) |
| Alcohol Swabs | Two per week (one for vial, one for injection site) |
| Sharps container | For safe disposal of used syringes and needles |
Important notes
- Always new, sterile insulin syringes for each injection.
- Systematically rotate injection sites (abdomen, thighs, upper arms).
- Inject slowly and steadily; wait a few seconds before withdrawing the needle.
- Administer on the same day each week; if missed, take within 5 days.
- Gradual dose escalation helps mitigate gastrointestinal side effects.
Frequently asked questions
How long does it take to see results with Semaglutide?
Results can vary, but significant weight loss is often observed over 16-20+ weeks, especially as you reach the maintenance dose. Consistency with the weekly injections and lifestyle adjustments are key.
What should I do if I miss a weekly dose of Semaglutide?
If you miss a dose, administer it as soon as you remember, provided it's within 5 days of your scheduled dose. If more than 5 days have passed, skip the missed dose and resume your regular schedule with the next planned injection.
Why is a gradual dose increase recommended for Semaglutide?
The gradual dose escalation, or titration, is crucial for improving tolerability and reducing the likelihood of gastrointestinal side effects like nausea and vomiting. It allows your body to adjust to the medication over time.
Can I use Semaglutide for purposes other than weight management?
While Semaglutide is primarily known for weight management and blood sugar control, it is also being researched for other potential health benefits. However, this protocol is specifically designed for chronic weight management based on established research. Always consult with a healthcare professional regarding any off-label uses.
Educational reference only. These figures summarise how Semaglutide is commonly described in research literature and supplier documentation, including the Semaglutide listing at peptidesuk4u.co.uk. They are not a prescription, not medical advice, and not a recommendation to self-administer anything.
Related protocols
Semaglutide (20 mg Vial)
Weekly GLP-1 agonist for weight loss and glucose control.
Semaglutide (30 mg Vial)
Weekly GLP-1 agonist for weight loss and glucose control.
Semaglutide (5 mg Vial)
Weekly injections for weight management and metabolic health.
Mazdutide (5 mg Vial)
Dual GLP-1/glucagon agonist for weight management and metabolic health.